Liquidia Corp (LQDA): Operating Cash Flow
-$35.69M
Year ended 2025-12-31
$167.71M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$35.69M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$93.42M | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$41.56M | n/m | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | -$28.59M | n/m | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | -$34.03M | n/m | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | -$54.14M | n/m | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | -$48.28M | n/a | 2021-03-25, From 2019-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Liquidia Corp (LQDA) | 2025-12-31 | -$35.69M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$27.59M | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$81.04M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $23.75M | +218.5% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$75.37M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$322.98M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$166.78M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$8.58M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $10.24M | -13.8% |
Compare LQDA, HRTX, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗